K vitamininin Kardiyovasküler Sağlık Üzerine Etkisi: Güncel Yaklaşımlar

K vitamini doğada filokinon ve menakinon olmak üzere iki şekilde bulunmaktadır. K vitamininin en bilinen biyokimyasal rolü gama (?-) glutamil karboksilaz enzimi için koenzim görevidir. En bilinen işlevi ise hepatik kan kaogülasyon faktörleri sentezi üzerinde gösterdiği etkidir. Son yıllarda K vitamininin kan koagülasyonu dışında vasküler hastalıkların önlenmesinde ve tedavisinde de etkili olduğu bildirilmektedir. Yapılan çalışmalarda K vitamini varfarin benzeri oral antikoagülan kullanımının koagülasyon faktörlerinin sentezini azaltarak, arteriyal tromboz riskini düşürdüğü bilinmektedir. Yeni yapılan çalışmalarda ise antikoagülan kullanımının K vitamini ile ilişkili olarak arteriyal kalsifikasyonlara neden olabileceği belirtilmektedir. Bu derleme yazıda K vitamininin kardiyovasküler hastalıklar, arter kalsifikasyonu ve ilaç etkileşimleri ile ilişkisi ele alınmıştır

The Effect of Vitamin K on Cardiovascular Health: Recent Current Approaches

Vitamin K is found in two forms in nature, phylliquinone and menaquinone. The most known biochemical role of vitamin K is the coenzym for gamma (γ-) glutamyl carboxylase enzyme. The most known function of vitamin K is the effect on hepatic blood coagulation factors synthesis. In recent years it has been reported that vitamin K is also effective in the prevention and treatment of vascular diseases besides blood coagulation. Studies have indicated that insufficient or low intake of vitamin K may be associated with arterial calcification. It is known that the use of warfarin-like oral anticoagulants reduces the risk of arterial thrombosis by reducing the synthesis of coagulation factors. In recent studies, it is stated that the use of anticoagulant may cause arterial calcifications in association with vitamin K. In this review article, vitamin K is discussed in relation to cardiovascular diseases, arterial calcification and drug interactions

PDF

___

1. Gröber U, Reichrath J, Holick MF, Kisters K. Vitamin K: an old vitamin in a new perspective. Dermatoendocrinol 2014;6:e968490.
2. Truong JT, Booth SL. Emerging issues in vitamin K research. J Evid Based Complement Altern Med 2011;16:73-79.
3. DiNicolantonio JJ, Bhutani J, O’Keefe, JH. The health benefits of vitamin K. Open Heart 2015;2:e000300.
4. Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost 2008;100:530-547.
5. Dalmeijer GW, Van Der Schouw YT, Beulens JWJ. Chapter 14 - Vitamin K, Coronary Calcification and Risk of Cardiovascular Disease. In: Preedy VR, editor. Bioactive Food as Dietary Interventions for Cardiovascular Disease. 1st ed. San Diego: Academic Press; 2013. p. 229-241.
6. Walther B, Karl JP, Booth SL, Boyaval P. Menaquinones, bacteria, and the food supply: the relevance of dairy and fermented food products to vitamin K requirements. Adv Nutr 2013;4:463-473.
7. Booth SL, Lichtenstein AH, Dallal GE. Phylloquinone absorption from phylloquinone-fortified oil is greater than from a vegetable in younger and older men and women. J Nutr 2002;132:2609-2612.
8. Jones KS, Bluck LJ, Wang LY, Stephen AM, Prynne CJ, Coward WA. The effect of different meals on the absorption of stable isotope-labelled phylloquinone. Br J Nutr 2009;102:1195-1202.
9. Schurgers LJ,Vermeer C. Determination of phylloquinone and menaquinones in food. Pathophysiol Haemost Thromb 2001;30:298-307.
10. World Health Organization. Global atlas on cardiovascular disease prevention and control. Available at: http://www.who.int/cardiovascular_diseases/ publications/atlas_ cvd/en/ Acecessed February 10, 2017.
11. Shea MK, Holden RM. Vitamin K status and vascular calcification: evidence from observational and clinical studies. Adv Nutr 2012;3:158-165.
12. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010;303:1610-1616.
13. Türkiye’ye Özgü Besin ve Beslenme Rehberi. Yenilenmiş 1. Baskı. Hacettepe Üniversitesi Sağlık Bilimleri Fakültesi Beslenme ve Diyetetik Bölümü, Ankara, 2015.
14. Theuwissen E, Magdeleyns E, Braam L, Teunissen K, Knapen M, Binnekamp I, et al. Vitamin K status in healthy volunteers. Food Funct 2014;5:229-234.
15. Vermeer C. Vitamin K: the effect on health beyond coagulation - an overview. Adv Food Nutr Res 2012;56:5329-5335.
16. Folsom AR, Kronmal RA, Detrano RC, O’Leary DH, Bild DE, Bluemke DA, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: The Multi-Ethnic Study Of Atherosclerosis (MESA). Arch Intern Med 2008;168:1333-1339.
17. Dalmeijer GW, Van Der Schouw YT, Booth SL, De Jong PA, Beulens JW. Phylloquinone concentrations and the risk of vascular calcification in healthy women. Arterioscler Thromb Vasc Biol 2014;34:1587-1590.
18. Beulens JWJ, Booth SL, Van Den Heuvel EGHM, Stoecklin E, Baka A, Vermeer C. The role of menaquinones (vitamin K2) in human health. Br J Nutr 2013;110:1357-1368.
19. Schurgers LJ, Teunissen KJ, Knapen MH, Kwaijtaal M, Van Diest R, Appels A, et al. Novel conformationspecific antibodies against matrix γ-carboxyglutamic acid (Gla) protein undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005;25:1629-1633.
20. Cranenburg EC, Schurgers LJ, Vermeer C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost 2007;98:120-125.
21. Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, Van Der Meer IM, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr 2004;134:3100-3105.
22. Gast GCM, De Roos NM, Sluijs I, Bots ML, Beulens JWJ, Geleijnse JM, et al. A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis 2009;19:504-510.
23. Erkkila AT, Booth SL, Hu FB, Jacques PF, Manson JE, Rexrode KM, et al. Phylloquinone intake as a marker for coronary heart disease risk but not stroke in women. Eur J Clin Nutr 2004;59:196-204.
24. Erkkilä AT, Booth SL, Hu FB, Jacques PF, Lichtenstein AH. Phylloquinone intake and risk of cardiovascular diseases in men. Nutr Metab Cardiovasc Dis 2007;17:58- 62.
25. Rees K, Guraewal S, Wong YL, Majanbu DL, Mavrodaris A, Stranges S, et al. Is vitamin K consumption associated with cardio-metabolic disorders? A systematic review. Maturitas 2010;67:121-128.
26. Braam L, McKeown N, Jacques P, Lichtenstein A, Vermeer C, Wilson P, et al. Dietary phylloquinone intake as a potential marker for a heart-healthy dietary pattern in the Framingham Offspring cohort. J Am Diet Assoc 2004;104:1410-1414.
27. Jie KSG, Bots ML, Vermeer C, Witteman JCM, Grobbee DE. Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: a populationbased study. Atherosclerosis 1995;116:117-123.
28. Villines TC, Hatzigeorgiou C, Feuerstein IM, O’Malley PG, Taylor AJ. Vitamin K1 intake and coronary calcification. Coron Artery Dis 2005;16:199-203.
29. Maas AH, Van Der Schouw YT, Beijerinck D, Deurenberg JJ, Willem PTM, Grobbee DE, et al. Vitamin K intake and calcifications in breast arteries. Maturitas 2007;56:273-279.
30. Beulens JWJ, Bots ML, Atsma F, Bartelink MLEL, Prokop M, Geleijnse JM, et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis 2009;203:489-493.
31. Braam L, Hoeks AP, Brouns F, Hamulyák K, Gerichhausen MJ, Vermeer C. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost 2004;91:373-380.
32. Shea MK, O’Donnell CJ, Hoffmann U, Dallal GE, Dawson-Hughes B, Ordovas JM, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr 2009;89:1799-1807.
33. Shea MK, Booth SL, Miller ME, Burke GL, Chen H, Cushman M, et al. Association between circulating vitamin K1 and coronary calcium progression in community-dwelling adults: the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr 2013;98:197-208.
34. Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH, Landewé RB, et al. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost 2010;104:811.
35. Schurgers LJ, Cranenburg ECM, Vermeer C. Matrix Gla-protein: The calcification inhibitor in need of vitamin K. Thromb Haemost 2008;100:593-603.
36. Heuvel EGHM, Van Schoor NM, Lips P, Magdeleyns EJP, Deeg DJH, Vermeer C, et al. Circulating uncarboxylated matrix Gla protein, a marker of vitamin K status, as a risk factor of cardiovascular disease. Maturitas 2014;77:137-141.
37. Dalmeijer GW, Van Der Schouw YT, Magdeleyns EJ, Vermeer C, Verschuren WMM, Boer JMA, et al. Circulating desphospho-uncarboxylated matrix γ-carboxyglutamate protein and the risk of coronary heart disease and stroke. J Thromb Haemost 2014;12:1028-1034.
38. Booth SL. Roles for vitamin K beyond coagulation. Annu Rev Nutr 2009;29:89-110.
39. Poterucha TJ, Goldhaber SZ. Warfarin and Vascular Calcification. Am J Med 2016;129:635.e631-635.e634.
40. Tantisattamo E, Han KH, O’Neill WC. Increased vascular calcification in patients receiving warfarin significance. Arterioscler Thromb Vasc Biol 2015;35:237-242.
41. Han KH, O’Neill WC. Increased peripheral arterial calcification in patients receiving warfarin. J Am Heart Assoc 2016;5:e002665.
42. Schurgers LJ, Aebert H, Vermeer C, Bültmann B, Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood 2004;104:3231-3232.
43. El Asmar MS, Naoum JJ, Arbid EJ. Vitamin K dependent proteins and the role of itamin K2 in the modulation of vascular calcification: a review. Oman Med J 2014;29:172-177.
44. Rennenberg RJMW, Van Varik BJ, Schurgers LJ, Hamulyak K, Ten Cate H, Leiner T, et al. Chronic coumadin treatment is associated with increased extracoronary arterial calcification in humans. Blood 2010;115:5121-5123.
45. Schurgers LJ, Spronk HM, Soute BA, Schiffers PM, DeMey JG, Vermeer C. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007;109:2823-2831.